We applied our 20 years of epigenomic expertise to assist Universal Diagnostics (UDx) in developing a unique and customized early-detection workflow for colorectal cancer (CRC). This approach combines liquid biopsies with DNA methylation technologies for biomarker discovery and subsequent biomarker validation.
 |
Capturing biomarkers in real-time with liquid biopsy Using cell-free DNA (cfDNA) isolated from plasma, biomarkers were monitored in real-time in the risk population. |
We helped identify the best sample prep options in terms of quantity, quality, reproducibility and high-throughput for regular screening of cfDNA from plasma. |
 |
DNA methylation for cancer classification Genome-wide methylation profiles from healthy and cancer patients were created to identify potential biomarkers. |
Using our WGBS/EM-seq service, UDx identified DNA methylation patterns associated with each CRC grade. |
 |
Validating biomarkers for performance Once a pool of potential biomarkers was available, we identified the best performers. |
Thanks to our Targeted Methyl-seq service, UDx narrowed down the candidates, and we validated a set of biomarkers that performs reliably with an NGS assay. |
Kristi Kruusmaa
Chief Scientific Officer
Universal Diagnostics
